Skip to main content
Fig. 5 | Translational Neurodegeneration

Fig. 5

From: p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease

Fig. 5

p85S6K expression is specifically decreased in human AD brains and  5×FAD mouse brains. a, b Expression of p85S6K/p70S6K and phosphorylated p85S6K in P2 pellets from fractionation of postmortem temporal cortex from human AD brains and non-demented control (Ctl). n = 13 for Ctl and n = 17 for AD. t = 0.8582, df = 27, P = 0.3984 for p-p85S6K, Mann–Whitney U = 39, P = 0.0021 for p85S6K, Mann–Whitney U = 107, P = 0.9016 for p70S6K. c Pearson correlation of Braak stage and the expression level of p85S6K in human brains. d–f Expression of p85S6K/p70S6K and phosphorylated p85S6K in P2 pellets from fractionation of cortex (d, e) and hippocampus (d, f) from 7-month-old  5×FAD mice. n = 4 mice per group. t = 0.9933, df = 6, P = 0.3589; t = 4.005, df = 6, P = 0.0238; t = 0.7484, df = 6, P = 0.4825 (e, from left to right panels). t = 0.9035, df = 6, P = 0.4011; t = 3.548, df = 6, P = 0.0121; t = 2.221, df = 6, P = 0.0681 (f, from left to right panels). Data are presented as mean ± SEM. Mann–Whitney test, two-tailed (b, middle and right panels) and unpaired t test, two-tailed (b, left panel; and e, f). *P < 0.05, **P < 0.01

Back to article page